Floatz Rating
CC42/100
Confidence
Indicative
Sponsor
Sumitomo Pharma America, Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
32Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02729298CT.gov First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Colorectal Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dubermatinib (this asset) | Sumitomo Pharma America, Inc. | P1 | CC · 42 |
| Tipiracil | Mayo Clinic | P2 | BB |
| Fluorouracilum | City of Hope Medical Center | P4 | BB |
| Oxaliplatin | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Capecitabine | First Affiliated Hospital of Zhejiang University | P4 | BB |
| Irinotecan | City of Hope Medical Center | P3 | BB |
| Muamycin | City of Hope Medical Center | P3 | BB |
| Pembrolizumab | Roswell Park Cancer Institute | P3 | B |
| Cyclophosphamide | City of Hope Medical Center | P3 | B |
+42 more in the Colorectal Carcinoma cohort
Other indications for Dubermatinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Small Cell Lung Carcinoma | — | P1 | CC · 47 |
| Acute Myeloid Leukemia | — | P1/2 | CC · 45 |
| Ovarian Carcinoma | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dubermatinib in Colorectal Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dubermatinib-colorectal-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →